Author:
Zhou Liang,Zhang Yahui,Chen Wenyu,Niu Niu,Zhao Junjie,Qi Weibo,Xu Yufen
Abstract
Abstract
Objective
This study aimed to construct a nomogram to effectively predict the overall survival (OS) of patients with early-stage non-small-cell lung cancer (NSCLC).
Methods
For the training and internal validation cohorts, a total of 26,941 patients with stage I and II NSCLC were obtained from the Surveillance, Epidemiology, and End Results (SEER) database. A nomogram was constructed based on the risk factors affecting prognosis using a Cox proportional hazards regression model. And 505 patients were recruited from Jiaxing First Hospital for external validation. The discrimination and calibration of the nomogram were evaluated by C-index and calibration curves.
Results
A Nomogram was created after identifying independent prognostic factors using univariate and multifactorial factor analysis. The C-index of this nomogram was 0.726 (95% CI, 0.718–0.735) and 0.721 (95% CI, 0.709–0.734) in the training cohort and the internal validation cohort, respectively, and 0.758 (95% CI, 0.691–0.825) in the external validation cohort, which indicates that the model has good discrimination. Calibration curves for 1-, 3-, and 5-year OS probabilities showed good agreement between predicted and actual survival. In addition, DCA analysis showed that the net benefit of the new model was significantly higher than that of the TNM staging system.
Conclusion
We developed and validated a survival prediction model for patients with non-small cell lung cancer in the early stages. This new nomogram is superior to the traditional TNM staging system and can guide clinicians to make the best clinical decisions.
Funder
Natural Science Foundation of Zhejiang province
the Key Discipline of Jiaxing Medicine Construction Project
the Jiaxing Key Laboratory of Precision Treatment for Lung Cancer,Scientific Technology Plan Program for Healthcare in Zhejiang Province
Science and technology project of Jiaxing
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference38 articles.
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.
2. Wu F, Wang L, Zhou C. Lung cancer in China: current and prospect. Curr Opin Oncol. 2021;33(1):40–6.
3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.
4. Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL, Siegel RL. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363–85.
5. Noone A, Howlader N, Krapcho M. SEER Cancer Statistics Review, 1975–2015; Based on November 2017 SEER data submission, posted to the SEER website April 2018. Bethesda: National Cancer Institute; 2018. p. 2019.